| Screening for Colorectal (Bowel) Cancer |
|
|
Prevention and early detection of colorectal cancer is important, many patients do not show symptoms until the disease has reached an advanced stage; screening may help detect changes before they become cancerous, or catch the cancer at an early stage. Screening may by targeted at populations thought to have a higher risk of developing colorectal cancer (for example those over age 50, particularly those with a 1st degree relative dignosed with colorectal cancer, or familial predispostion to adenomatous polyposis).
Menu: Screening for Colorectal (Bowel) Cancer
Information for Patients and the Public
Information for Health Professionals / Researchers
Latest Research Publications
Colorectal (Bowel) CancerInformation Patients and the Public (8 links)
- Colorectal Cancer Screening
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Colorectal Cancer Screening
National Cancer Institute
PDQ summaries are written and frequently updated by editorial boards of experts Further info. - Bowel cancer screening and prevention
Cancer Research UK
CancerHelp information is examined by both expert and lay reviewers. Content is reviewed every 12 to 18 months. Further info.
Statistics for the UK, including incidence, mortality, survival, risk factors and stats related to treatment and symptom relief. - How to complete the NHS bowel cancer screening test
Beating Bowel Cancer
Video by the charity Beating Bowel Cancer, media doctor Chris Steele explains in easy to follow steps how to complete the NHS bowel cancer screening test. 'It's as easy as 1,2,3 and it could save your life'. - Animated Medicine: Bowel Cancer
Remedica / NHS
Separate tutorials for health professionals and also for the public. - Colorectal Cancer Control Program (CRCCP)
Centers for Disease Control and Prevention (CDC) - National Bowel Cancer Screening Program
National Bowel Cancer Screening Program - NHS Bowel Cancer Screening Programme
NHS Bowel Cancer Screening Programme
The programme began in 2006 and achieved national coverage in 2010. People aged 60+ are offered a faecal occult blood test and if indicated undergo investigations, such as coloscopy.
Information for Health Professionals / Researchers (5 links)
- PubMed search for publications about Screening for Colorectal Cancer - Limit search to: [Reviews]
PubMed Central search for free-access publications about Screening for Colorectal Cancer
US National Library of Medicine
PubMed has over 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Constantly updated. - Screening for Colorectal (Bowel) Cancer
Patient UK
PatientUK content is peer reviewed. Content is reviewed by a team led by a Clinical Editor to reflect new or updated guidance and publications. Further info. - Animated Medicine: Bowel Cancer
Remedica / NHS
Separate tutorials for health professionals and also for the public. - NHS Bowel Cancer Screening Programme
NHS Bowel Cancer Screening Programme
The programme began in 2006 and achieved national coverage in 2010. People aged 60+ are offered a faecal occult blood test and if indicated undergo investigations, such as coloscopy. - Screening for colorectal cancer using the faecal occult blood test, Hemoccult
Cochrane Systematic Reviews
Hewitson P, Glasziou PP, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD001216. DOI: 10.1002/14651858.CD001216.pub2
Latest Research Publications
This list of publications is regularly updated (Source: PubMed).
The impact of colorectal cancer screening in a veteran hospital population.
Am Surg. 2013; 79(3):296-300 [PubMed]
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study.
Ann Intern Med. 2013; 158(5 Pt 1):312-20 [PubMed]
OBJECTIVE: To examine the association between screening colonoscopy and risk for incident late-stage colorectal cancer (CRC).
DESIGN: Nested case-control study.
SETTING: Four U.S. health plans.
PATIENTS: 1039 average-risk adults enrolled for at least 5 years in one of the health plans. Case patients were aged 55 to 85 years on their diagnosis date (reference date) of stage IIB or higher (late-stage) CRC during 2006 to 2008. One or 2 control patients were selected for each case patient, matched on birth year, sex, health plan, and prior enrollment duration.
MEASUREMENTS: Receipt of CRC screening 3 months to 10 years before the reference date, ascertained through medical record audits. Case patients and control patients were compared on receipt of screening colonoscopy or sigmoidoscopy by using conditional logistic regression that accounted for health history, socioeconomic status, and other screening exposures.
RESULTS: In analyses restricted to 471 eligible case patients and their 509 matched control patients, 13 case patients (2.8%) and 46 control patients (9.0%) had undergone screening colonoscopy, which corresponded to an adjusted odds ratio (AOR) of 0.29 (95% CI, 0.15 to 0.58) for any late-stage CRC, 0.36 (CI, 0.16 to 0.80) for right colon cancer, and 0.26 (CI, 0.06 to 1.11; P = 0.069) for left colon/rectum cancer. Ninety-two case patients (19.5%) and 173 control patients (34.0%) had screening sigmoidoscopy, corresponding to an AOR of 0.50 (CI, 0.36 to 0.70) overall, 0.79 (CI, 0.51 to 1.23) for right colon late-stage cancer, and 0.26 (CI, 0.14 to 0.48) for left colon cancer.
LIMITATION: The small number of screening colonoscopies affected the precision of the estimates.
CONCLUSION: Screening with colonoscopy in average-risk persons was associated with reduced risk for diagnosis of incident late-stage CRC, including right-sided colon cancer. For sigmoidoscopy, this association was seen for left CRC, but the association for right colon late-stage cancer was not statistically significant.
An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial.
Ann Intern Med. 2013; 158(5 Pt 1):301-11 [PubMed]
OBJECTIVE: To determine whether interventions using electronic health records (EHRs), automated mailings, and stepped increases in support improve CRC screening adherence over 2 years.
DESIGN: 4-group, parallel-design, randomized, controlled comparative effectiveness trial with concealed allocation and blinded outcome assessments. (ClinicalTrials.gov: NCT00697047)
SETTING: 21 primary care medical centers.
PATIENTS: 4675 adults aged 50 to 73 years not current for CRC screening.
INTERVENTION: Usual care, EHR-linked mailings ("automated"), automated plus telephone assistance ("assisted"), or automated and assisted plus nurse navigation to testing completion or refusal ("navigated"). Interventions were repeated in year 2.
MEASUREMENTS: The proportion of participants current for screening in both years, defined as colonoscopy or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonoscopy, or sigmoidoscopy (year 2).
RESULTS: Compared with those in the usual care group, participants in the intervention groups were more likely to be current for CRC screening for both years with significant increases by intensity (usual care, 26.3% [95% CI, 23.4% to 29.2%]; automated, 50.8% [CI, 47.3% to 54.4%]; assisted, 57.5% [CI, 54.5% to 60.6%]; and navigated, 64.7% [CI, 62.5% to 67.0%]; P < 0.001 for all pair-wise comparisons). Increases in screening were primarily due to increased uptake of FOBT being completed in both years (usual care, 3.9% [CI, 2.8% to 5.1%]; automated, 27.5% [CI, 24.9% to 30.0%]; assisted, 30.5% [CI, 27.9% to 33.2%]; and navigated, 35.8% [CI, 33.1% to 38.6%]).
LIMITATION: Participants were required to provide verbal consent and were more likely to be white and to participate in other types of cancer screening, limiting generalizability.
CONCLUSION: Compared with usual care, a centralized, EHR-linked, mailed CRC screening program led to twice as many persons being current for screening over 2 years. Assisted and navigated interventions led to smaller but significant stepped increases compared with the automated intervention only. The rapid growth of EHRs provides opportunities for spreading this model broadly.
Nurse observation during colonoscopy increases polyp detection: a randomized prospective study.
Am J Gastroenterol. 2013; 108(2):166-72 [PubMed]
METHODS: Consecutive patients undergoing screening colonoscopy were prospectively randomized to routine colonoscopy or physician and nurse observation during withdrawal.
RESULTS: Of 502 patients, 249 were randomized to routine colonoscopy, and 253 to physician plus nurse observation during withdrawal. A total of 592 polyps were detected, 40 identified by the endoscopy nurse only. With nurse observation, 1.32 polyps and 0.82 adenomas were found per colonoscopy, vs. 1.03 polyps and 0.64 adenomas in the routine group, demonstrating a 1.29-fold and a 1.28-fold increase in the average number of polyps and of adenomas detected, respectively. The overall adenoma detection rate (ADR) was 44.1%, with trends toward increased ADR and all-polyp detection rate with nurse observation.
CONCLUSIONS: Nurse observation during colonoscopy resulted in an increase in the number of polyps and adenomas found per colonoscopy, along with a trend toward improved overall ADR and all-polyp detection rate.
Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark.
BMJ. 2013; 346:e8441 [PubMed]
DESIGN: Meta-analysis of survival data from population based, randomized controlled trials comparing populations screened and not screened for breast or colorectal cancer. Trials were identified as high quality by reviews from the Cochrane Collaboration and United States Preventive Services Task Force.
SETTING: Trials undertaken in the United States, Denmark, United Kingdom, and Sweden.
POPULATION: Screened patients older than 40 years.
PRIMARY OUTCOME MEASURES: Time to death from breast or colorectal cancer in screened and control populations.
INTERVENTIONS: Fecal occult blood testing for colorectal cancer screening, mammography for breast cancer screening.
RESULTS: Our study included five and four eligible trials of breast and colorectal cancer screening, respectively. For breast cancer screening, 3.0 years (95% confidence interval 1.1 to 6.3) passed before one death from breast cancer was prevented for every 5000 women screened. On average across included studies, it took 10.7 years (4.4 to 21.6) before one death from breast cancer was prevented for 1000 women screened. For colorectal cancer screening, 4.8 years (2.0 to 9.7) passed before one death from colorectal cancer was prevented for 5000 patients screened. On average across included studies, it took 10.3 years (6.0 to 16.4) before one death from colorectal cancer was prevented for 1000 patients screened.
CONCLUSIONS: Our results suggest that screening for breast and colorectal cancer is most appropriate for patients with a life expectancy greater than 10 years. Incorporating time lag estimates into screening guidelines would encourage a more explicit consideration of the risks and benefits of screening for breast and colorectal cancer.
Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
J Clin Pathol. 2013; 66(4):330-4 [PubMed]
METHODS: Data from a single Trust was used. The Trust's pathology reporting system was searched retrospectively for all FOBt study requests in 1 year. In patients with a positive test, the Trust's clinical results reporting system was searched to determine the type and outcome of any investigations. Patients with positive tests were cross-matched with the Trust's colorectal cancer database to detect interval cancers.
RESULTS: 1363 FOB tests were requested during the calendar year. 715 (52.5%) were completed. Mean age was 60.6 years, 30.7% of patients were in the screening age group. 60 (4.4%) patients were FOBt positive. Total colonic imaging was performed in only 22% of those who were FOBt positive. Significant pathology was detected in five patients (0.4%) including three colonic carcinomas. There were no interval cancers in the FOBt-positive group.
CONCLUSIONS: The number of FOBt requests has increased with the introduction of a colorectal cancer screening programme. The FOBt completion rate and colonic imaging rate in FOBt-positive patients outside the national screening programme was low. Guidelines for the use of FOBt outside of screening are needed.
Colorectal cancer knowledge, attitudes, screening, and intergenerational communication among Japanese American families: an exploratory, community-based participatory study.
J Cross Cult Gerontol. 2013; 28(1):89-101 [PubMed] Article available free on PMC after 01/03/2014
Report on the expert forum on using information technology to facilitate uptake and impact of colorectal cancer screening guidelines.
Can J Gastroenterol. 2012; 26(12):902-4 [PubMed] Article available free on PMC after 01/12/2013
Does the use of sedation, or the level of sedation, affect detection during colonoscopy?
Am J Gastroenterol. 2012; 107(12):1849-51 [PubMed]
Cost-effectiveness of CT colonography.
Radiol Clin North Am. 2013; 51(1):89-97 [PubMed]
Communication about colorectal cancer screening in Britain: public preferences for an expert recommendation.
Br J Cancer. 2012; 107(12):1938-43 [PubMed] Article available free on PMC after 04/12/2013
METHODS: In face-to-face interviews, a population-based sample of adults across Britain (n=1964; age 50-80 years) indicated their preference between: (1) a strong recommendation to participate in CRC screening, (2) a recommendation alongside advice to make an individual decision, and (3) no recommendation but advice to make an individual decision. Other measures included trust in the NHS and preferences for information on benefits and risks.
RESULTS: Most respondents (84%) preferred a recommendation (47% strong recommendation, 37% recommendation plus individual decision-making advice), but the majority also wanted full information on risks (77%) and benefits (78%). Men were more in favour of a recommendation than women (86% vs 81%). Trust in the NHS was high overall, but the minority who expressed low trust were less likely to want a recommendation.
CONCLUSION: Most British adults want full information on risks and benefits of screening but they also want a recommendation from an authoritative source. An 'expert' view may be an important part of autonomous health decision-making.
Aid-assisted decision making and colorectal cancer screening: a randomized controlled trial.
Am J Prev Med. 2012; 43(6):573-83 [PubMed]
PURPOSE: To assess the impact of decision aid-assisted SDM on CRC screening uptake.
DESIGN: RCT.
SETTING/PARTICIPANTS: The study was conducted at an urban, academic safety-net hospital and community health center between 2005 and 2010. Participants were asymptomatic, average-risk patients aged 50-75 years due for CRC screening.
INTERVENTION: Study participants (n=825) were randomized to one of two intervention arms (decision aid plus personalized risk assessment or decision aid alone) or control arm. The interventions took place just prior to a routine office visit with their primary care providers.
MAIN OUTCOME MEASURES: The primary outcome was completion of a CRC screening test within 12 months of the study visit. Logistic regression was used to identify predictors of test completion and mediators of the intervention effect. Analysis was completed in 2011.
RESULTS: Patients in the decision-aid group were more likely to complete a screening test than control patients (43.1% vs 34.8%, p=0.046) within 12 months of the study visit; conversely, test uptake for the decision aid and decision aid plus personalized risk assessment arms was similar (43.1% vs 37.1%, p=0.15). Assignment to the decision-aid arm (AOR=1.48, 95% CI=1.04, 2.10), black race (AOR=1.52, 95% CI=1.12, 2.06) and a preference for a patient-dominant decision-making approach (AOR=1.55, 95% CI=1.02, 2.35) were independent determinants of test completion. Activation of the screening discussion and enhanced screening intentions mediated the intervention effect.
CONCLUSIONS: Decision aid-assisted SDM has a modest impact on CRC screening uptake. A decision aid plus personalized risk assessment tool is no more effective than a decision aid alone.
TRIAL REGISTRATION: This study is registered at www.clinicaltrials.govNCT00251862.
Association of eHealth literacy with colorectal cancer knowledge and screening practice among internet users in Japan.
J Med Internet Res. 2012; 14(6):e153 [PubMed] Article available free on PMC after 04/12/2013
OBJECTIVE: The present study examined associations between eHealth literacy, knowledge of CRC, and CRC screening practices.
METHODS: Data were analyzed for 2970 Japanese adults (men, 49.9%; mean age±SD, 39.7±10.9 years) who responded to an Internet-based cross-sectional survey. Knowledge of the definition of CRC, its risk factors and screening practice, previous experience of CRC screening, score on the Japanese version of the eHEALS (J-eHEALS), sociodemographic attributes (sex, age, marital status, educational attainment, and household income level), and frequency of Internet usage were obtained. Sociodemographic attributes and frequency of Internet usage were used as control variables in the multiple regression and logistic regression models.
RESULTS: eHealth literacy was positively associated with CRC knowledge (β=.116, <.001), when the covariables of both eHealth literacy and CRC knowledge were used in the multiple regression model. Moreover, after controlling for sociodemographic factors, which were significantly associated with eHealth literacy and CRC screening practice, an increase of 1 point in the eHEALS score signified that participants were 1.03 times (95% CI=1.01-1.05) more likely to undergo CRC screening.
CONCLUSIONS: Internet users with high eHealth literacy are more likely to have knowledge and previous screening practice related to CRC compared to those with low eHealth literacy.
Sedation in screening colonoscopy: impact on quality indicators and complications.
Am J Gastroenterol. 2012; 107(12):1837-48 [PubMed]
METHODS: We analyzed data of 52,506 screening colonoscopies performed by 196 endoscopists between November 2007 and April 2011 according to the Austrian "quality management for colon cancer prevention" program.
RESULTS: Sedation did not affect polyp detection rate (women P=0.7972, men P=0.3711) or ADR for both sexes (women P=0.2773, men P=0.8676). ADR was not significantly influenced by sedation (P=0.1272), but by age and sex (both P<0.0001), when the executing endoscopist was considered. Although women were more often sedated than men (90.70 vs. 81.83%; P<0.0001), CIR was slightly lower in women than in men (94.69 vs. 96.58%; P<0.0001). Sedation improved the CIR in women by 2.95% (94.96 vs. 92.01%; P<0.0001), whereas in men it was just by 1.28% (96.81 vs. 95.53%; P<0.0001). Sedated women only reached the CIR of unsedated men (94.96 vs. 95.53%; P=0.1005). Accounting for the intra-observer influence of the endoscopist, the overall CIR was influenced by the interaction of sex and age (P=0.0049), but not by sedation (P=0.1435).
CONCLUSIONS: Sedation does not increase adenoma or polyp detection, although it leads to an increase in CIR in men and women. This effect is more pronounced in women, yet CIR of men remains higher compared with women. Quality indicators are mainly influenced by the patient's age, sex, and the endoscopists' individual performance, rather than the endoscopists' subspeciality or procedural experience.
Anal cancer screening in HIV-infected patients: is it time to screen them all?
Dis Colon Rectum. 2012; 55(12):1244-50 [PubMed]
OBJECTIVE: The aim of this study was to examine the screening outcomes between HIV populations with and without these risk factors.
METHODS: We reviewed the records of all HIV patients referred for anal cytology and high-resolution anoscopy from June 2009 to June 2010. Patients were stratified into an increased-risk group or a standard-risk group.
MAIN OUTCOME: Of the 329 evaluable patients, 285 (89.8% men, 10.2% women, mean age 46 ± 10 years) were classified to the increased-risk group, whereas 44 (72.7% men, 27.3% women, mean age 52 ± 8 years) were included in the standard-risk group. Male sex, white race, sexual orientation, past and current receptive anal intercourse, noncompliance with condom use, and absence of a new sexual partner were significantly different in the increased-risk group in comparison with the standard-risk group. In the increased-risk group, 187 (66.5%) patients had biopsy-proven dysplasia of which 118 (42.0%) had high-grade disease. In the standard-risk group, 15 (34.9%) patients had biopsy-proven dysplasia of which 7 (16.3%) had high-grade disease. Cytology detected biopsy-confirmed high-grade dysplasia only in 23 of 118 (19.5%) patients in the increased-risk group and in 2 of 7 (28.6%) patients in the standard-risk group. Kappa agreement in detecting high-grade disease was low for both increased-risk and standard-risk groups: 0.16 (95% CI 0.07-0.23) and 0.40 (95% CI 0.02-0.40).
LIMITATIONS: Our study is a chart-based retrospective review of data with a small female population. Histology reports came from 2 different laboratories.
CONCLUSION: High-grade anal dysplasia was prevalent even among HIV patients who only have standard risk factors. Anal cytology and high-resolution anoscopy have poor agreement. We suggest considering annual screening by using high-resolution anoscopy in addition to cytology for all HIV patients regardless of risk factors.
Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.
Ann Intern Med. 2012; 157(9):611-20 [PubMed] Article available free on PMC after 04/12/2013
OBJECTIVE: To assess the effectiveness and costs of colonoscopy versus other rescreening strategies after an initial negative colonoscopy result.
DESIGN: Microsimulation model.
DATA SOURCES: Literature and data from the Surveillance, Epidemiology, and End Results program.
TARGET POPULATION: Persons aged 50 years who had no adenomas or cancer detected on screening colonoscopy.
TIME HORIZON: Lifetime.
PERSPECTIVE: Societal.
INTERVENTION: No further screening or rescreening starting at age 60 years with colonoscopy every 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical testing (FIT), or computed tomographic colonography (CTC) every 5 years.
OUTCOME MEASURES: Lifetime cases of colorectal cancer, life expectancy, and lifetime costs per 1000 persons, assuming either perfect or imperfect adherence.
RESULTS OF BASE-CASE ANALYSIS: Rescreening with any method substantially reduced the risk for colorectal cancer compared with no further screening (range, 7.7 to 12.6 lifetime cases per 1000 persons [perfect adherence] and 17.7 to 20.9 lifetime cases per 1000 persons [imperfect adherence] vs. 31.3 lifetime cases per 1000 persons with no further screening). In both adherence scenarios, the differences in life-years across rescreening strategies were small (range, 30 893 to 30 902 life-years per 1000 persons [perfect adherence] vs. 30 865 to 30 869 life-years per 1000 persons [imperfect adherence]). Rescreening with HSFOBT, FIT, or CTC had fewer complications and was less costly than continuing colonoscopy.
RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to test-specific adherence rates.
LIMITATION: Data on adherence to rescreening were limited.
CONCLUSION: Compared with the currently recommended strategy of continuing colonoscopy every 10 years after an initial negative examination, rescreening at age 60 years with annual HSFOBT, annual FIT, or CTC every 5 years provides approximately the same benefit in life-years with fewer complications at a lower cost. Therefore, it is reasonable to use other methods to rescreen persons with negative colonoscopy results.
PRIMARY FUNDING SOURCE: National Cancer Institute.
A randomized comparison of print and web communication on colorectal cancer screening.
JAMA Intern Med. 2013; 173(2):122-9 [PubMed] Article available free on PMC after 04/12/2013
METHODS: We identified unscreened women at average risk for CRC from the scheduling databases of obstetrics and gynecology practices in 2 large health care systems. Participants consented to a randomized controlled trial that compared CRC screening uptake after receipt of CRC screening information delivered via the web or in print form. Participants could also be assigned to a control (usual care) group. Women in the interventional arms received tailored information in a high- or low-monitoring Cognitive Social Information Processing model-defined attentional style. The primary outcome was CRC screening participation at 4 months.
RESULTS: A total of 904 women were randomized to the interventional or control group. At 4 months, CRC screening uptake was not significantly different in the web (12.2%), print (12.0%), or control (12.9%) group. Attentional style had no effect on screening uptake for any group. Some baseline participant factors were associated with greater screening, including higher income (P = .03), stage of change (P < .001), and physician recommendation to screen (P < .001).
CONCLUSIONS: A web-based educational intervention was no more effective than a print-based one or control (no educational intervention) in increasing CRC screening rates in women at average risk of CRC. Risk messages tailored to attentional style had no effect on screening uptake. In average-risk populations, use of the Internet for health communication without additional enhancement is unlikely to improve screening participation.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00459030.
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention.
J Clin Oncol. 2012; 30(32):3947-52 [PubMed] Article available free on PMC after 10/11/2013
PATIENTS AND METHODS: Veterans Affairs (VA) administrative data were used to construct four cross-sectional groups of veterans at average risk, age 50 to 64 years; one group was created for each of the following years: 2006, 2007, 2009, and 2010. We applied hospital fixed effects for estimation, using a difference-in-differences model in which the eight hospitals served as the intervention sites, and the other 121 hospitals served as controls, with 2006 to 2007 as the preintervention period and 2009 to 2010 as the postintervention period.
RESULTS: The sample included 4,352,082 veteran-years in the 4 years. The adherence rates were 37.6%, 31.6%, 34.4%, and 33.2% in the intervention sites in 2006, 2007, 2009, and 2010, respectively, and the corresponding rates in the controls were 31.0%, 30.3%, 32.3%, and 30.9%. Regression analysis showed that among those eligible for screening, the intervention was associated with a 2.2-percentage point decrease in likelihood of adherence (P < .001). Additional analyses showed that the intervention was associated with a 5.6-percentage point decrease in likelihood of screening colonoscopy among the adherent, but with increased total colonoscopies (all indicators) of 3.6 per 100 veterans age 50 to 64 years.
CONCLUSION: The intervention had little impact on CRC screening rates for the studied population. This absence of favorable impact may have been caused by an unintentional shift of limited VA colonoscopy capacity from average-risk screening to higher-risk screening and to CRC surveillance, or by physician fatigue resulting from the large number of clinical reminders implemented in the VA.
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Principles of evidence assessment and methods for reaching recommendations.
Endoscopy. 2012; 44 Suppl 3:SE9-14 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Quality assurance in endoscopy in colorectal cancer screening and diagnosis.
Endoscopy. 2012; 44 Suppl 3:SE88-105 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing.
Endoscopy. 2012; 44 Suppl 3:SE65-87 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Evaluation and interpretation of screening outcomes.
Endoscopy. 2012; 44 Suppl 3:SE49-64 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Organisation.
Endoscopy. 2012; 44 Suppl 3:SE31-48 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Communication.
Endoscopy. 2012; 44 Suppl 3:SE164-85 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Introduction.
Endoscopy. 2012; 44 Suppl 3:SE15-30 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Management of lesions detected in colorectal cancer screening.
Endoscopy. 2012; 44 Suppl 3:SE140-50 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Annotations of colorectal lesions.
Endoscopy. 2012; 44 Suppl 3:SE131-9 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Quality assurance in pathology in colorectal cancer screening and diagnosis.
Endoscopy. 2012; 44 Suppl 3:SE116-30 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Professional requirements and training.
Endoscopy. 2012; 44 Suppl 3:SE106-15 [PubMed]
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Executive summary.
Endoscopy. 2012; 44 Suppl 3:SE1-8 [PubMed]
This page last updated: 22nd May 2013
Displaying links verified within last 2 weeks at time of update.
